Patients with psoriasis respond to continuous open-label etanercept treatment after initial incomplete response in a randomized, placebo-controlled trial - 09/08/11
, Boni Elewski, MD b, Kim Papp, MD c, Andrea Wang, MS d, Ralph Zitnik, MD d, Angelika Jahreis, MD d
Correspondence to: Gerald G. Krueger, MD, University of Utah Health Sciences Center; Division of Dermatology, 30 N 1900 East, Bldg 4B454, Salt Lake City, UT 84132-0001.Salt Lake City, Utah; Birmingham, Alabama; Waterloo and London, Ontario, Canada; and Thousand Oaks, California
Abstract |
Background |
Etanercept provides rapid, significant improvement in psoriatic symptoms and disease.
Objective |
The effectiveness of continued etanercept treatment beyond 24 weeks in patients who initially did not achieve at least a 50% improvement from baseline in the Psoriasis Area and Severity Index (PASI 50) was assessed.
Methods |
Patients with moderate to severe plaque psoriasis received 50 mg open-label, subcutaneous etanercept per week after completing blinded therapy with placebo or 1 of 3 doses of etanercept. The PASI was measured.
Results |
Irrespective of prior dosing regimens, 43% of 157 patients who did not attain PASI 50 responses at week 24 achieved PASI 50 responses at week 36; 55% achieved PASI 50 responses at week 60. Etanercept was safe and well tolerated.
Limitations |
Interpretation of these results is limited by the open-label design of the analysis.
Conclusion |
More than half of patients who initially had an inadequate response to treatment achieved satisfactory responses with continued etanercept therapy. The safety profile of etanercept in these patients and in patients who had more immediate responses was similar.
Le texte complet de cet article est disponible en PDF.Abbreviations used : DLQI, DSGAP, PASI, PGA, USP, TNF
Plan
| Supported by Amgen Inc and Wyeth Research. Funded by Immunex Corporation, Seattle, Wash, a wholly owned subsidiary of Amgen Inc, Thousand Oaks, Calif, and by Wyeth. Data were collected by Amgen and stored in a central repository. Amgen provided statistical and editorial support. Conflicts of interest: Dr Krueger has participated on the speakers bureau and ad hoc advisory boards for Amgen. Dr Elewski is a clinical investigator for Amgen, Biogen, Centocor, and Genentech. Dr Papp has no financial interest in Amgen but has served as a principal investigator, advisory board member, and speaker. Ms Wang and Drs Zitnik and Jahreis are employees of and have been granted stock options in Amgen, Inc. Reprints not available from the authors. |
Vol 54 - N° 3S2
P. S112-S119 - mars 2006 Retour au numéro
Article précédent
- Efficacy of etanercept in an integrated multistudy database of patients with psoriasis
- Kenneth Gordon, Neil Korman, Ellen Frankel, Huei Wang, Angelika Jahreis, Ralph Zitnik, Ting Chang
- Case reports of etanercept in inflammatory dermatoses
- Robert Norman, Robert G. Greenberg, J. Mark Jackson
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?